Dianthus Therapeutics, Inc. /DE/ (DNTH)

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients with severe autoimmune and inflammatory diseases. It was incorporated in Delaware in June 2015 as Magenta Therapeutics. On September 11, 2023, it completed a reverse merger with Former Dianthus (incorporated in Delaware in May 2019), changed its name, and took on primarily the business conducted by Former Dianthus.

The lead product candidate is DNTH103, a proprietary, fully human monoclonal IgG4 antibody. It is engineered to bind only the active form of the C1s complement protein, inhibiting the classical complement pathway while leaving the lectin and alternative pathways intact. It uses YTE half-life extension technology and is designed for lower-dose, less frequent, self-administered subcutaneous injection with a pre-filled pen. A Phase 1 trial in 60 healthy volunteers across eight dose cohorts showed a half-life of about 60 days, classical pathway inhibition with 300mg subcutaneous dosing every two weeks, and no serious adverse events or complement-related infections. A global Phase 2 trial in generalized myasthenia gravis began in the first quarter of 2024 after FDA clearance of the IND. The company plans Phase 2 trials in multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy in 2024, subject to regulatory authorizations. It also expects to nominate a development candidate for an additional complement target in the second half of 2024.

The initial target market is generalized myasthenia gravis, with estimated U.S. prevalence of about 70,000 to 90,000 individuals. Estimated U.S. prevalence is up to about 10,000 for multifocal motor neuropathy and about 15,000 for chronic inflammatory demyelinating polyneuropathy. In myasthenia gravis, DNTH103 could compete with intravenous immunoglobulin, FcRn inhibitors such as Vyvgart, and C5 complement inhibitors such as Soliris and Ultomiris. The C5 inhibitors carry an FDA Boxed Warning and a REMS program for meningococcal infection risk. The company believes DNTH103 may avoid these through its selective mechanism.

On strategy and operations, the company holds worldwide rights to DNTH103 except Greater China, which it licensed in June 2022 to Zenas BioPharma. It intends to pursue independent development and commercialization in select indications and markets, while opportunistically exploring licensing, collaborations or partnerships. The Phase 1 trial was conducted in New Zealand. The text does not describe suppliers, manufacturing, or headquarters location.